EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Caffeine as a Treatment for Perinatal Hypoxic-Ischemic Brain Injury: The Potential Risks and Benefits

Kelly Qishan Zhou, Flora Lam, Laura Bennet, Alistair Jan Gunn, Joanne O Davidson

Developmental Neuroscience · 2025

DOI: 10.1159/000545126 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Developmental Neuroscience, 2025. Verfasst von Kelly Qishan Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, The University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Caffeine, Hypoxia-Ischemia, Brain, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: It is well established that therapeutic hypothermia improves outcomes for infants with moderate-severe hypoxic-ischemic encephalopathy (HIE) in high-income counties. However, ∼29% of the infants treated with therapeutic hypothermia still have adverse outcome. Additionally, therapeutic hypothermia is not recommended as a treatment for infants with HIE in low- and middle-income countries. Therefore, there is an urgent need to develop alternative treatments for infants with HIE in low- and middle-income countries, as well as additive treatments to therapeutic hypothermia in high-income countries. Summary: Caffeine is widely used as an agent to prevent apnea in preterm infants, and more recently, it has been investigated as a potential neuroprotective treatment for perinatal hypoxic-ischemic (HI) brain injury, but the preclinical evidence so far has been mixed. Furthermore, there are concerns that caffeine, which is an adenosine receptor antagonist, could abolish the endogenous neuroprotective effects of adenosine, during and after HI. Key Messages: Further studies using caffeine particularly in large animal translational models of HI brain injury are required to establish the safety and efficacy of caffeine for HIE before conducting large randomized controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaffeineHypoxia-Ischemia, BrainNeuroprotective AgentsHumansAnimalsInfant, NewbornHypothermia, Induced

Stichwörter der Autor:innen

Brain injuryCaffeineHypoxia-ischemiaNeuroprotection

Substanzen

CaffeineNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Physiology, The University of Auckland, Auckland, New Zealand.
  • Department of Physiology, The University of Auckland, Auckland, New Zealand, joanne.davidson@auckland.ac.nz.

Zitieren

APA

Zhou, K. Q., Lam, F., Bennet, L., Gunn, A. J., & Davidson, J. O. (2025). Caffeine as a Treatment for Perinatal Hypoxic-Ischemic Brain Injury: The Potential Risks and Benefits. Developmental Neuroscience. https://doi.org/10.1159/000545126

Vancouver

Zhou KQ, Lam F, Bennet L, Gunn AJ, Davidson JO. Caffeine as a Treatment for Perinatal Hypoxic-Ischemic Brain Injury: The Potential Risks and Benefits. Developmental Neuroscience. 2025. doi:10.1159/000545126

BibTeX
@article{Zhou2025,
  author = {Zhou, Kelly Qishan and Lam, Flora and Bennet, Laura and Gunn, Alistair Jan and Davidson, Joanne O},
  title = {Caffeine as a Treatment for Perinatal Hypoxic-Ischemic Brain Injury: The Potential Risks and Benefits},
  journal = {Developmental Neuroscience},
  year = {2025},
  doi = {10.1159/000545126}
}
Kostenlos starten →